Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{3fa1efba61d244819c6a3ec180f0d26d,
title = "Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential",
abstract = "Polycystic ovary syndrome (PCOS) is associated with increased risk of venous thromboembolism (VTE) and cardiovascular disease (CVD) in later life. We aimed to study the effect of liraglutide intervention on some markers of VTE and CVD, in PCOS. In a double-blind, placebo-controlled, randomized trial 72 overweight and/or insulin resistant women with PCOS were randomized, in a 2:1 ratio, to liraglutide or placebo 1.8 mg/day. Endpoints included between-group difference, from baseline to 26-week follow-up, in change in thrombin generation test parameters: Endogenous thrombin potential, peak thrombin concentration, lag-time and time-to-peak, and in levels of plasminogen activator inhibitor-1. Mean weight loss was 5.2 kg (95{\%}CI 3.0-7.5 kg, p<0.001) in the liraglutide group compared with placebo. We detected no effect on endogenous thrombin potential in either group. In the liraglutide group peak thrombin concentration decreased by 16.71 nmol/L (95{\%}CI 2.32-31.11, p<0.05) and lag-time and time-to-peak increased by 0.13 min (95{\%}CI 0.01-0.25, p<0.05) and 0.38 min (95{\%}CI 0.09-0.68, p<0.05), respectively, but there were no between-group differences. Plasminogen activator inhibitor-1 decreased by 12{\%} (95{\%}CI 0-23, p=0.05) with liraglutide and there was a trend towards 16{\%} (95{\%}CI -4-32, p=0.10) reduction, compared with placebo. In overweight women with PCOS, liraglutide intervention caused an approximate 5{\%} weight loss. In addition, liraglutide affected thrombin generation, although not significantly differently from placebo. A concomitant trend towards improved fibrinolysis indicates a possible reduction of the baseline thrombogenic potential. The findings point towards beneficial effects of liraglutide on markers of VTE and CVD risk, which should be further pursued in larger studies.",
author = "Malin Nylander and Signe Fr{\o}ssing and Caroline Kistorp and Jens Faber and Skouby, {Sven Olaf}",
year = "2017",
month = "1",
day = "24",
doi = "10.1530/EC-16-0113",
language = "English",
volume = "6",
pages = "89--99",
journal = "Endocrine Connections",
issn = "2049-3614",
publisher = "BioScientifica Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Liraglutide in polycystic ovary syndrome

T2 - a randomized trial, investigating effects on thrombogenic potential

AU - Nylander, Malin

AU - Frøssing, Signe

AU - Kistorp, Caroline

AU - Faber, Jens

AU - Skouby, Sven Olaf

PY - 2017/1/24

Y1 - 2017/1/24

N2 - Polycystic ovary syndrome (PCOS) is associated with increased risk of venous thromboembolism (VTE) and cardiovascular disease (CVD) in later life. We aimed to study the effect of liraglutide intervention on some markers of VTE and CVD, in PCOS. In a double-blind, placebo-controlled, randomized trial 72 overweight and/or insulin resistant women with PCOS were randomized, in a 2:1 ratio, to liraglutide or placebo 1.8 mg/day. Endpoints included between-group difference, from baseline to 26-week follow-up, in change in thrombin generation test parameters: Endogenous thrombin potential, peak thrombin concentration, lag-time and time-to-peak, and in levels of plasminogen activator inhibitor-1. Mean weight loss was 5.2 kg (95%CI 3.0-7.5 kg, p<0.001) in the liraglutide group compared with placebo. We detected no effect on endogenous thrombin potential in either group. In the liraglutide group peak thrombin concentration decreased by 16.71 nmol/L (95%CI 2.32-31.11, p<0.05) and lag-time and time-to-peak increased by 0.13 min (95%CI 0.01-0.25, p<0.05) and 0.38 min (95%CI 0.09-0.68, p<0.05), respectively, but there were no between-group differences. Plasminogen activator inhibitor-1 decreased by 12% (95%CI 0-23, p=0.05) with liraglutide and there was a trend towards 16% (95%CI -4-32, p=0.10) reduction, compared with placebo. In overweight women with PCOS, liraglutide intervention caused an approximate 5% weight loss. In addition, liraglutide affected thrombin generation, although not significantly differently from placebo. A concomitant trend towards improved fibrinolysis indicates a possible reduction of the baseline thrombogenic potential. The findings point towards beneficial effects of liraglutide on markers of VTE and CVD risk, which should be further pursued in larger studies.

AB - Polycystic ovary syndrome (PCOS) is associated with increased risk of venous thromboembolism (VTE) and cardiovascular disease (CVD) in later life. We aimed to study the effect of liraglutide intervention on some markers of VTE and CVD, in PCOS. In a double-blind, placebo-controlled, randomized trial 72 overweight and/or insulin resistant women with PCOS were randomized, in a 2:1 ratio, to liraglutide or placebo 1.8 mg/day. Endpoints included between-group difference, from baseline to 26-week follow-up, in change in thrombin generation test parameters: Endogenous thrombin potential, peak thrombin concentration, lag-time and time-to-peak, and in levels of plasminogen activator inhibitor-1. Mean weight loss was 5.2 kg (95%CI 3.0-7.5 kg, p<0.001) in the liraglutide group compared with placebo. We detected no effect on endogenous thrombin potential in either group. In the liraglutide group peak thrombin concentration decreased by 16.71 nmol/L (95%CI 2.32-31.11, p<0.05) and lag-time and time-to-peak increased by 0.13 min (95%CI 0.01-0.25, p<0.05) and 0.38 min (95%CI 0.09-0.68, p<0.05), respectively, but there were no between-group differences. Plasminogen activator inhibitor-1 decreased by 12% (95%CI 0-23, p=0.05) with liraglutide and there was a trend towards 16% (95%CI -4-32, p=0.10) reduction, compared with placebo. In overweight women with PCOS, liraglutide intervention caused an approximate 5% weight loss. In addition, liraglutide affected thrombin generation, although not significantly differently from placebo. A concomitant trend towards improved fibrinolysis indicates a possible reduction of the baseline thrombogenic potential. The findings point towards beneficial effects of liraglutide on markers of VTE and CVD risk, which should be further pursued in larger studies.

U2 - 10.1530/EC-16-0113

DO - 10.1530/EC-16-0113

M3 - Journal article

VL - 6

SP - 89

EP - 99

JO - Endocrine Connections

JF - Endocrine Connections

SN - 2049-3614

IS - 2

ER -

ID: 49809786